Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy

International Archives of Allergy and Immunology

Volumn 148, Issue 3, 2009, Pages 251-260

  Schubert, R ^a,c   Eickmeier, O ^a   Garn, H ^b   Baer, P C ^a   Mueller, T ^a   Schulze, J ^a   Rose, M A ^a   Rosewich, M ^a   Renz, H ^b   Zielen, S ^a  

^a GOETHE UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Blocking antibodies; Cluster; Immunogenicity; Mite; Specific immunotherapy; T cell subset transcription factors

Indexed keywords

CD63 ANTIGEN; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; NOVO HELISEN; PEPTIDOLEUKOTRIENE; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLERGIC ASTHMA; ANAPHYLAXIS; ARTICLE; ASTHMA; BASOPHIL; BLOOD SAMPLING; CELL ACTIVATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG SAFETY; DYSPNEA; ERYTHEMA; FEMALE; HOUSE DUST ALLERGY; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INJECTION SITE PAIN; INJECTION SITE REDNESS; INJECTION SITE SWELLING; MAINTENANCE DRUG DOSE; MALE; OPEN STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION;

ADOLESCENT; ANTIGENS, CD; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; BASOPHILS; BREATH TESTS; CHILD; DESENSITIZATION, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL CATIONIC PROTEIN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LEUKOTRIENES; MALE; NITRIC OXIDE; PLATELET MEMBRANE GLYCOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES;

EID: 53449090330     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000161585     Document Type: Article

References (38)

1. Passalacqua G, Durham SR: Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007;119:881-891.
2. Finegold I: Allergen immunotherapy: present and future. Allergy Asthma Proc 2007;28:44-49.
3. Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558-562.
4. Malling HJ: Immunotherapy as an effective tool in allergy treatment. Allergy 1998;53:461-472.
5. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-475.
6. Klimek L, Dormann D, Jarman ER, Cromwell O, Riechelmann H, Reske-Kunz AB: Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin Exp Allergy 1999;29:1326-1335.
7. Klimek L, Malling HJ: Specific immunotherapy (hyposensitization) in allergic rhinoconjunctivitis. Meta-analysis of effectiveness and side effects (in German). HNO 1999;47:602-610.
8. Tabar AI, Echechipia S, Garcia BE, Olaguibel JM, Lizaso MT, Gomez B, Aldunate MT, Martin S, Marcotegui F: Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus . J Allergy Clin Immunol 2005;116:109-118.
9. Mauro M, Russello M, Alesina R, Sillano V, Alessandrini A, Dama A, Passalacqua G, Senna G: Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. Eur Ann Allergy Clin Immunol 2006;38:31-34.
10. Tabar AI, Muro MD, Garcia BE, Alvarez MJ, Acero S, Rico P, Olaguíbel JM: Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy. J Investig Allergol Clin Immunol 1999;9:155-164.
11. Moreno C, Fernandez-Tavora L, Acero S, Alonso MD, Barahona MJ, Blanco R, Cisteró A, Conde J, Fernández J, Fernández S, Fernández-Rivas M, García BE, García-Rodríguez R, Camacho E, González-Quevedo T, Gonzalo A, Guardia P, Sánchez-Cano M, Tabar AI, de la Torre F: Tolerance of a cluster schedule on the treatment of seasonal allergic respiratory disease with pollen extracts quantified in mass units. J Investig Allergol Clin Immunol 2003;13:221-227.
12. Tabar AI, Fernandez-Tavora L, Alonso R, Castillo R, Cistero-Bahima A, de la Torre-Morin F, Fernández J, García-Figueroa BE, Fernández S, García-González JJ, García-Robaina JC, Moreno F, Lobatón P, Sánchez-Machín I, de la Torre-Martínez F: Tolerance of a cluster schedule with a house dust mite extract quantified in mass units: multicentre study. J Investig Allergol Clin Immunol 2004;14:193-197.
13. Durham SR, Till SJ: Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102:157-164.
14. Rossi RE, Monasterolo G, Coco G, Silvestro L, Operti D: Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Vaccine 2007;25:957-964.
15. Garcia BE, Sanz ML, Gato JJ, Fernandez J, Oehling A: IgG4 blocking effect on the release of antigen-specific histamine. J Investig Allergol Clin Immunol 1993;3:26-33.
16. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR: Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252-3259.
17. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR: Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-4194.
18. Francis JN, Till SJ, Durham SR: Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003;111:1255-1261.
19. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA: IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205-1214.
20. Cockcroft DW, Killian DN, Mellon JJ, Hargreave FE: Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977;7:235-243.
21. Rosewich M, Rose MA, Eickmeier O, Travaci M, Kitz R, Zielen S: Montelukast as add-on therapy to beta-agonists and late airway response. Eur Respir J 2007;30:56-61.
22. Hansen I, Hormann K, Stuck BA, Schneider-Gene S, Mosges R, Klimek L: Cluster-immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal) (in German). Laryngorhinootologie 2003;82:558-563.
23. Halken S: Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention. Pediatr Allergy Immunol 2004;15:4-5, 9-32.
24. Barnes PJ, Liew FY: Nitric oxide and asthmatic inflammation. Immunol Today 1995;16:128-130.
25. Ohashi Y, Nakai Y, Kakinoki Y, Ohno Y, Sakamoto H, Kato A, Tanaka A: Effect of immunotherapy on serum levels of eosinophil cationic protein in perennial allergic rhinitis. Ann Otol Rhinol Laryngol 1997;106:848-853.
26. Bez C, Schubert R, Kopp M, Ersfeld Y, Rosewich M, Kuehr J, Kamin W, Berg AV, Wahn U, Zielen S: Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy 2004;34:1079-1085.
27. Cevit O, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB: Specific allergen immunotherapy: effect on immunologic markers and clinical parameters in asthmatic children. J Investig Allergol Clin Immunol 2007;17:286-291.
28. Keskin O, Tuncer A, Adalioglu G, Sekerel BE, Sackesen C, Kalayci O: The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Pediatr Allergy Immunol 2006;17:396-407.
29. Wachholz PA, Durham SR: Induction of 'blocking' IgG antibodies during immunotherapy. Clin Exp Allergy 2003;33:1171-1174.
30. van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, Ipsen H: Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999;163:2944-2952.
31. Bousquet J, Maasch H, Martinot B, Hejjaoui A, Wahl R, Michel FB: Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:439-446.
32. Wachholz PA, Soni NK, Till SJ, Durham SR: Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003;112:915-922.
33. Larche M: Regulatory T cells in allergy and asthma. Chest 2007;132:1007-1014.
34. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J: Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27:1131-1139.
35. Marcotte GV, Braun CM, Norman PS, Nicodemus CF, Kagey-Sobotka A, Lichtenstein LM, Essayan DM: Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 1998;101:506-513.
36. Abramson MJ, Puy RM, Weiner JM: Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995;151:969-974.
37. Cohn JR, Pizzi A: Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993;91:734-737.
38. Lower T, Henry J, Mandik L, Janosky J, Friday GA Jr: Compliance with allergen immunotherapy. Ann Allergy 1993;70:480-482.